Working… Menu

A Phase III Trial Comparing Two Dose-dense, Dose-intensified Approaches (ETC and PM(Cb)) for Neoadjuvant Treatment of Patients With High-risk Early Breast Cancer (GeparOcto)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02125344
Recruitment Status : Completed
First Posted : April 29, 2014
Last Update Posted : July 13, 2017
Roche Pharma AG
Teva Pharmaceuticals USA
Vifor Pharma
Information provided by (Responsible Party):
German Breast Group